Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Will the tills ring for Iovance?
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Lack of overall survival doesn't stop Flaura2
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
The complex web of PARP inhibitor development
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
